ADGM

Business Context and Reporting Period

Company: Adagio Medical Holdings, Inc. (ADGM)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: Adagio is a medical technology company developing ablation technologies for cardiac arrhythmias, specifically ventricular tachycardia (VT) using its vCLAS Cryoablation System. The company received FDA Breakthrough Device designation in April 2025. Following a business combination in July 2024, the company is classified as a "Successor" for accounting purposes, with prior periods labeled "Predecessor."

Key Financial Metrics

Per Share Data (Successor): Basic Net Loss per share was $(0.26) for the three months and $(0.76) for the six months ended June 30, 2025. Diluted Net Loss per share was $(0.35) and $(0.86), respectively.

Material Changes vs. Prior Period

• Revenue: Revenue was $0 for the three and six months ended June 30, 2025, compared to $254,000 and $280,000 in the same periods of 2024. The decline is attributed to a pause in commercial activity in Europe and an inventory buyback.
• Operating Expenses: Total operating expenses decreased by 32% ($2.2 million) for the three months and 23% ($3.6 million) for the six months compared to 2024. This reduction is primarily due to a "corporate prioritization initiative" implemented in February 2025, which reduced headcount and focused resources on clinical trials.
• Net Loss: Net loss improved by 31% ($1.8 million) for the three months and 11% ($1.4 million) for the six months compared to the prior year periods, driven by lower operating expenses.
• Cash Position: Cash and cash equivalents decreased from $20.6 million at December 31, 2024, to $8.2 million at June 30, 2025, reflecting a net cash burn of $11.9 million from operating activities over the six-month period.

Guidance, Outlook, and Risks

Going Concern: The company has disclosed substantial doubt about its ability to continue as a going concern. Management estimates current cash resources will fund operations only into the fourth quarter of 2025. Additional financing (equity or debt) is required to complete clinical development and commercialization.

Outlook:

• Clinical Trials: The FULCRUM-VT pivotal clinical trial is currently enrolling and is expected to complete in the second half of 2025, with FDA submission anticipated thereafter.
• Cost Management: The company is executing cost-cutting measures and has paused commercial activity in Europe to preserve cash.
• Regulatory: The company relies on obtaining FDA approval for its vCLAS system; Breakthrough Device designation does not guarantee approval.

Risks and Contingencies:

• Liquidity Risk: Inability to raise additional capital could force the company to delay or terminate R&D and commercialization efforts.
• Trade Policy: Potential tariffs on international suppliers (including China) could increase costs, which may be difficult to pass on to customers due to fixed pricing contracts.
• Corporate Prioritization: The recent restructuring carries risks of losing institutional knowledge and decreased employee morale.

Investor Verification Checklist

• Cash Runway: Verify the timeline for securing additional financing given the "substantial doubt" disclosure and cash burn rate of ~$6 million per quarter.
• Revenue Strategy: Confirm the timeline for resuming commercial sales in Europe and the strategy for U.S. market entry post-FDA approval.
• Debt Obligations: Review the terms of the $16.9 million Convertible Securities Notes (13% interest, convertible at $10.00/share) and potential dilution upon conversion.
• Clinical Milestones: Monitor enrollment progress and data readouts for the FULCRUM-VT trial, which is critical for future valuation.
• Impairment History: Note the significant goodwill and intangible asset impairments ($49.2 million total) recorded in late 2024 due to share price declines; assess if further impairments are likely.